Shareholder Alert: Ademi LLP investigates whether Zynerba Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Harmony

MILWAUKEE, Aug. 28, 2023 /PRNewswire/ -- Ademi LLP is investigating Zynerba (Nasdaq: ZYNE) for possible breaches of fiduciary duty and other violations of law in its transaction with Harmony.

Click here to learn how to join the action https://www.ademilaw.com/case/zynerba-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995.  There is no cost or obligation to you.

In the transaction, Zynerba stockholders are expected to receive only $1.1059 per share in cash, or $60 million in the aggregate, plus one non-tradeable contingent value right (CVR) per share, representing the right to receive potential additional payments of up to $140 million in the aggregate, subject to the achievement of certain clinical, regulatory and sales milestones. The transaction agreement unreasonably limits competing transactions for Zynerba by imposing a significant penalty if Zynerba accepts a competing bid. Zynerba insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of Zynerba's board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

If you own Zynerba common stock and wish to obtain additional information, please contact Guri Ademi either at gademi@ademilaw.com or toll-free: 866-264-3995, or https://www.ademilaw.com/case/zynerba-pharmaceuticals-inc.                        

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Ademi LLP                                                                    
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-ademi-llp-investigates-whether-zynerba-pharmaceuticals-inc-has-obtained-a-fair-price-in-its-transaction-with-harmony-301911115.html

SOURCE Ademi LLP